Table 4.
All immune-related adverse events (N = 36)
| No. (%) | |||||
|---|---|---|---|---|---|
| Any grade | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Any events | 31 (86.1) | 30 (83.3) | 2 (5.6) | 2 (5.6) | 3 (8.3) |
| Cutaneous | |||||
| Reactive cutaneous capillary endothelial proliferation | 25 (69.4) | 24 (66.7) | 0 | 1 (2.8) | 0 |
| Pruritus | 5 (13.9) | 5 (13.9) | 0 | 0 | 0 |
| Rash | 1 (2.8) | 1 (2.8) | 0 | 0 | 0 |
| Endocrine | |||||
| Thyroid dysfunction | 6 (16.7) | 4 (11.1) | 2 (5.6) | 0 | 0 |
| Hyperglycemia | 6 (16.7) | 5 (13.9) | 0 | 1 (2.8) | 0 |
| Others | |||||
| Immune-related myocarditis | 2 (5.6) | 0 | 0 | 0 | 2 (5.6) |
| Immune-related hepatitis | 1 (2.8) | 0 | 0 | 0 | 1 (2.8) |
| Immune-related pneumonia | 1 (2.8) | 0 | 0 | 0 | 1 (2.8) |
| Immune-related myositis | 1 (2.8) | 0 | 0 | 0 | 1 (2.8) |
| Immune-related neuritis | 1 (2.8) | 0 | 0 | 0 | 1 (2.8) |
No grade 5 immune-related adverse events occurred.